Faeth Therapeutics (FTH) Net Cash Flow (2020 - 2026)

Faeth Therapeutics (FTH) has reported Net Cash Flow for 7 consecutive years, with -$125.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Net Cash Flow fell 4779.93% year-over-year to -$125.4 million; the trailing twelve-month figure through Jun 2026 stood at $14.3 million (up 2054.05% YoY), and the FY2025 full-year result was -$1.3 million, up 56.05% from the prior year.
• Net Cash Flow retreated to -$125.4 million in Q2 2026 per FTH's latest filing, from $143.7 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $143.7 million in Q1 2026 and bottomed at -$125.4 million in Q2 2026.
• Historically, Net Cash Flow has averaged $1.1 million across 5 years, with a median of $1.2 million in 2022.
• The widest YoY moves for Net Cash Flow: up 122883.76% in 2026, down 4779.93% in 2026.
• Over 5 years, Net Cash Flow stood at $6.3 million in 2022, then sank by 73.71% to $1.7 million in 2023, then tumbled by 647.78% to -$9.1 million in 2024, then soared by 79.27% to -$1.9 million in 2025, then sank by 6522.07% to -$125.4 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$125.4 million, $143.7 million, and -$1.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.